In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue…
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective…
New York, Aug. 31, 2025 (GLOBE NEWSWIRE) -- August 31, 2025 | New York CrazyBulk proudly announces the release of…
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- August 31, 2025 08:30 ET | Source: Amarin…
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…
RIYADH, Saudi Arabia, Aug. 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC), ranked 15th globally…
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…